// App-Quantinova.ai

5013 : A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.

Researchers

Presenter

  • Kim N. Chi

Principal Investigators

  • Thian San Kheoh

  • Charles J. Ryan

  • Howard I. Scher

  • Arturo Molina

  • Joaquim Bellmunt

  • Nicholas J. Vogelzang

  • Dana E. Rathkopf

  • Karim Fizazi

  • Philip W. Kantoff

  • Jinhui Li

  • Johann Sebastian De Bono

Medical Centers

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Janssen Research & Development, LLC, Raritan, NJ

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Janssen Research & Development, Los Angeles, CA

  • Hospital Del Mar, Barcelona, Spain

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Locations

  • Canada

  • Spain

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00638690

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved